TY  - JOUR
AU  - Primac, Irina
AU  - Tabury, Kevin
AU  - Tasdogan, Alpaslan
AU  - Baatout, Sarah
AU  - Herrmann, Ken
TI  - The molecular blueprint of targeted radionuclide therapy.
JO  - Nature reviews / Clinical oncology
VL  - nn
SN  - 1759-4774
CY  - New York, NY
PB  - Nature Publ. Group
M1  - DKFZ-2025-01874
SP  - nn
PY  - 2025
N1  - epub
AB  - Targeted radionuclide therapy (TRT) is a cutting-edge treatment approach in oncology that combines the molecular precision of targeted agents with the effect of radiotherapy to selectively deliver cytotoxic radiation to cancer cells. Research efforts from the past few decades have led to a diverse molecular landscape of TRT and have provided lessons for further rational development of targeted radiopharmaceuticals and expansion of the clinical applications of this treatment modality. In this Review, we discuss TRT in the context of therapeutic approaches currently available in oncology, describe the broad range of established and emerging targets for TRT including innovative approaches to exploit vulnerabilities presented by the tumour microenvironment, and address the challenges for clinical translation and molecular optimization. By bridging technological innovation and preclinical discoveries with real-world clinical implementation, ongoing research on TRT is seeking to provide effective and safe treatment options for patients across a variety of cancer types and treatment settings. Overall, we emphasize the transformative potential of TRT and highlight how a comprehensive understanding of what constitutes an optimal target can redefine clinical practice, fostering the evolution of TRT as a highly individualized and adaptable therapeutic option that improves outcomes across a broad range of cancer types.
LB  - PUB:(DE-HGF)16
C6  - pmid:40926013
DO  - DOI:10.1038/s41571-025-01069-z
UR  - https://inrepo02.dkfz.de/record/304482
ER  -